C93025
All
Both

MALE

Treatment Groups	Eosinophil Percentage %	Hematocrit %	Hematocrit Manual %	Hemoglobin g per dL	Lymphocyte Percentage %	Mean Cell Hemoglobin pg
			Day 96	i		
ppm	1.6 ± 1.5	48.4 ± 1.1	49.5 ± 1.2	15.7 ± 0.3	83.7 ± 5.6	15.9 ± 0.2
5 ppm	1 ± 0.8	47.2 ± 1	48.1 ± 1.2	15.2 ± 0.4	83.9 ± 6.4	15.6 ± 0.3
5 ppm	1.9 ± 1.7	47.5 ± 2.1	48.6 ± 2.1	15.5 ± 0.7	84.7 ± 3.2	16 ± 0.3
0 ppm	1.5 ± 1.2	47.5 ± 1	48.2 ± 1*	15.5 ± 0.4	80.9 ± 5.1	16.2 ± 0.4
0 ppm	1.2 ± 0.9	46.8 ± 1.3**	48.2 ± 1.2*	15.7 ± 0.4	86.4 ± 3.7	16.9 ± 0.3**
20 ppm	1.5 ± 1.4	45.6 ± 1.3**	47.2 ± 0.7**	16.1 ± 0.4	81.3 ± 7	17.8 ± 0.4**

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.

MALE

Treatment Groups	Mean Cell Hemoglobin Concentration g per dL	Mean Corpuscular Volume fL	Monocyte Percentage %	Nucleated Rbc Count 1000 per uL	Platelet Count 1000 per uL	Red Blood Cell Count million per uL
			Day 9	6		
) ppm	32.5 ± 0.4	49 ± 0.8	2.2 ± 2.3	2.4 ± 0.9	731.6 ± 53.2	9.9 ± 0.2
7.5 ppm	32.3 ± 0.6	48.4 ± 0.5	1.2 ± 1.5	2.2 ± 0.6	730.9 ± 34.4	9.8 ± 0.2
l5 ppm	32.6 ± 0.6	49 ± 0.7	1.7 ± 1.6	2.7 ± 0.8	759.6 ± 32.2	9.7 ± 0.4
30 ppm	32.6 ± 0.4	49.6 ± 1	2.7 ± 2	2.7 ± 0.7	760 ± 42.1	9.6 ± 0.2**
60 ppm	33.6 ± 0.5**	50.3 ± 0.7**	1.7 ± 1.2	2.8 ± 0.6	785.5 ± 37*	9.3 ± 0.3**
20 ppm	35.3 ± 0.5**	50.4 ± 0.8**	2 ± 0.9	3.7 ± 1.3*	817.7 ± 30.5**	9.1 ± 0.3**

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.

MALE

Treatment Groups	Reticulocyte Percentage count per 100 RBC	Segmented Neutrophil Percentage %	
			Day 96
0 ppm	15.2 ± 5.3	12.4 ± 4.3	
7.5 ppm	17.7 ± 5.5	13.9 ± 5.6	
15 ppm	23.5 ± 8.9	11.7 ± 4.3	
30 ppm	16.8 ± 7.2	14.9 ± 4.8	
60 ppm	24.2 ± 6.7**	10.7 ± 4.2	
120 ppm	27.1 ± 9.7**	15.2 ± 6.2	

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.

Treatment Groups	Eosinophil Percentage %	Hematocrit %	Hematocrit Manual %	Hemoglobin g per dL	Lymphocyte Percentage %	Mean Cell Hemoglobin pg
			Day 96	j		
0 ppm	0.8 ± 0.9	48.8 ± 0.9	49.2 ± 1.1	16 ± 0.4	90.4 ± 2.4	16.2 ± 0.3
7.5 ppm	1.2 ± 0.6	48.8 ± 1.5	49.9 ± 1.3	16 ± 0.4	89.1 ± 3.5	16.2 ± 0.2
15 ppm	0.9 ± 1.1	47.7 ± 1.1	49.4 ± 1.4	15.8 ± 0.5	91.4 ± 3.9	16.5 ± 0.3
30 ppm	0.4 ± 0.5	47.6 ± 1.7	49.1 ± 1.6	15.7 ± 0.5	91.9 ± 2.8	16.5 ± 0.3*
60 ppm	1 ± 1.1	46.9 ± 1.5**	48.3 ± 1.7	15.7 ± 0.5	88.3 ± 5.5	16.7 ± 0.3**
120 ppm	0.6 ± 0.7	45.8 ± 1.3**	47.5 ± 1.5*	16 ± 0.5	87.8 ± 4.3	17.9 ± 0.4**

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.

FEMALE

Treatment Groups	Mean Cell Hemoglobin Concentration g per dL	Mean Corpuscular Volume fL	Monocyte Percentage %	Nucleated Rbc Count 1000 per uL	Nucleated Rbc Per 100 Wbc per 100 WC	Platelet Count 1000 per uL
			Day 9	6		
0 ppm	32.8 ± 0.4	49.3 ± 0.5	0.6 ± 1.1	2.7 ± 0.6	0 ± 0	723.3 ± 52.1
7.5 ppm	32.9 ± 0.7	49.3 ± 0.8	0.5 ± 1.1	2.6 ± 0.5	0 ± 0	761.7 ± 62.8
15 ppm	33.1 ± 0.6	49.6 ± 0.5	0.3 ± 0.7	2.5 ± 0.3	0.1 ± 0.3	752.1 ± 50.2
30 ppm	33.1 ± 0.5	49.9 ± 0.6*	0.4 ± 0.7	2.6 ± 0.7	0.1 ± 0.3	740.7 ± 44.4
60 ppm	33.4 ± 0.4*	50.1 ± 0.6**	0.7 ± 1.6	3.3 ± 1.1	0.2 ± 0.4	827.7 ± 40.5**
120 ppm	35 ± 0.6**	51.3 ± 0.7**	0.6 ± 0.8	3 ± 0.8	0 ± 0	827.2 ± 71.3**

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.

FEMALE

		·	
Treatment	Red Blood Cell	Reticulocyte	Segmented
Groups	Count	Percentage	Neutrophil
	million per uL	count per 100	Percentage
		RBC	%
			Day 96
0 ppm	9.9 ± 0.2	26.8 ± 4.8	8.2 ± 1.6
7.5 ppm	9.9 ± 0.3	27.1 ± 4.6	9.2 ± 3.3
15 ppm	9.6 ± 0.2*	28.4 ± 6.7	7.4 ± 3.8
30 ppm	9.5 ± 0.3*	34 ± 5*	7.3 ± 2.4
60 ppm	9.4 ± 0.3**	38.1 ± 4.7**	10 ± 4.4
120 ppm	8.9 ± 0.2**	41.6 ± 7.1**	11 ± 4.6

** END OF REPORT **

*p < 0.05

**p < 0.01

NOTE: Table is to include results for each time point samples were analyzed. Similar table is to be included for hematology parameters.